Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
Tirzepatide causes the most fat loss of any diabetes drug but at the cost of muscle; SGLT2 inhibitors preserve muscle better—helping doctors tailor choices to individual priorities.
This NMA of 41 RCTs (n=2,906) quantifies how antidiabetic drugs differentially affect body composition: tirzepatide (dual GIP/GLP-1 agonist) delivers the largest fat mass reduction but at the cost of significant lean body mass loss, while SGLT2 inhibitors cause modest fat loss with minimal lean impact. The trade-off between fat and lean mass with GLP-1/GIP agonists has important implications for clinical counseling, exercise prescription, and drug selection in patients concerned about functional outcomes.
What the study was
- Study design
- Systematic review and network meta-analysis (NMA) of 41 RCTs; frequentist random-effects framework
- Population
- 2,906 participants with diabetes across 41 RCTs evaluating antidiabetic drugs
- Sample size
- 2906
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes, Obesity and Metabolism
Why it surfaced
NMA of 41 RCTs directly comparing all major antidiabetic drug classes on body composition — the most clinically consequential outcome beyond glycemia for GLP-1/GIP agonists. Tirzepatide's superior fat reduction but lean mass trade-off is actionable for clinical decision-making and patient counseling on drugs now widely prescribed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.